Other News To Note
Friday, May 20, 2011
Sutro Biopharma Inc., of South San Francisco, said that a study published in the July 2010 issue of Biotechnology and Bioengineering showed that its biochemical protein synthesis technology platform enabled fast, high-yield protein synthesis and scale-up. In the study, a bioactive cytokine human granulocyte-macrophage colony-stimulating factor was produced at titers of 700 mg/L in 10 hours from frozen extract of Sutro's E.coli-based open cell-free synthesis system.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.